NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/06/2024
Voltar para busca
Dado oficial do USPTO
RG
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
11/06/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
24/08/2021
Data de registro
11/06/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/06/2024
Última transação
11/06/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
09/02/2024
Primeiro uso no comércio
09/02/2024
Código do desenho
3
Tipo de titular
99
Localização do titular
Suzhou, Jiangsu, CN
Examinador
STEEL, ALYSSA
Unidade examinadora
N60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized illustration of the letters "R" and "G", which illustration is also meant to be a stylized presentation of the DNA double helix structure.
Titulares e representantes
Titulares
RinuaGene Biotechnology Co., Ltd.
Representantes
Eric Lamb Frost Brown Todd LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicalbiologicalpharmaceuticalveterinary preparations containing polypeptide encoding nucleic acids for the prevention and treatment of rare diseasescancersneurological disorderscardiovascular disordersinflammatory disordersimmunoregulatory disordersmetabolic disordersinfectious disorders and reproductive disorders;medicalbiologicalpharmaceuticalveterinary preparations for medical and pharmaceutical usepreparations for preventing and treating rare diseasescancersneurological disorderscardiovascular disordersinflammatory disordersimmunoregulatory disordersmetabolic disordersinfectious disordersreproductive disorders; RNA-based therapeutics and therapeutic agents for in vitro preparation and in vivoex vivoon vivo delivery to cell sites; cell-based immunotherapeutic treatment by way of genetically modified cellsmedicated serums for the treatment of rare diseasescancersneurological disorderscardiovascular disordersinflammatory disordersimmunoregulatory disordersmetabolic disordersinfectious disorders and reproductive disorders; attenuated viruses and particles similar to virusesencapsulated nucleic acids for the treatment of rare diseasescancersneurological disorderscardiovascular disordersinflammatory disordersimmunoregulatory disordersmetabolic disordersinfectious disorders and reproductive disorders; diagnostic reagents and diagnostic preparations for medical purposes; chemical reagents used for medical or veterinary purposes; biochemical reagents used for medical or veterinary purposes for the treatment of cancertreatment of immunological diseasestreatment of infectious diseases; adjuvants for medical purposes; macromoleculesnucleic acid sequences and proteinsused for medical and veterinary purposes; a full line of pharmaceuticalsvaccinesmedicinesbiologicsbiotherapeuticsbiosimilars and therapeutics for the treatment of infectious diseases and cancer; vaccines; a full line of pharmaceuticalsmedicinesbiologicsbiotherapeuticsbiosimilars and therapeutics for the treatment of infectious diseases and cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
11/06/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/05/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/05/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/05/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/05/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/05/2024
DPCC
DIVISIONAL PROCESSING COMPLETE
08/05/2024
EX3G
SOU EXTENSION 3 GRANTED
08/05/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
23/04/2024
IUAF
USE AMENDMENT FILED
12/04/2024
DRRR
DIVISIONAL REQUEST RECEIVED
12/04/2024
EXT3
SOU EXTENSION 3 FILED
12/04/2024
EISU
TEAS STATEMENT OF USE RECEIVED
12/04/2024
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
12/04/2024
EEXT
SOU TEAS EXTENSION RECEIVED
12/04/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
13/10/2023
EX2G
SOU EXTENSION 2 GRANTED
11/10/2023
EXT2
SOU EXTENSION 2 FILED
11/10/2023
EEXT
SOU TEAS EXTENSION RECEIVED
11/10/2023
DOCK
ASSIGNED TO EXAMINER
04/10/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/04/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/04/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/04/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22/03/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
20/03/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
20/03/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
20/03/2023
EX1G
SOU EXTENSION 1 GRANTED
20/03/2023
EXT1
SOU EXTENSION 1 FILED
20/03/2023
EEXT
SOU TEAS EXTENSION RECEIVED
20/03/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
18/10/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/08/2022
PUBO
PUBLISHED FOR OPPOSITION
23/08/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/08/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/07/2022
WOAG
WITHDRAWAL OF ATTORNEY GRANTED
15/07/2022
WOAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
15/07/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/07/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/07/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/07/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/06/2022
GNRT
NON-FINAL ACTION E-MAILED
09/06/2022
CNRT
NON-FINAL ACTION WRITTEN
09/06/2022
DOCK
ASSIGNED TO EXAMINER
26/05/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
12/10/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/10/2021
NWAP
NEW APPLICATION ENTERED
27/08/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RG ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.